3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-1-[4-((1E)-3-carboxyprop-1-enyl)benzyl]-7-methyl-1H-indole | 887338-15-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-1-[4-((1E)-3-carboxyprop-1-enyl)benzyl]-7-methyl-1H-indole
• 英文别名: 3-(2,3,4,6-tetra-O-benzyl-beta-D-glucopyranosyl)-1-[4-((1E)-3-carboxyprop-1-enyl)benzyl]-7-methyl-1H-indole；(E)-4-[4-[[7-methyl-3-[(2S,3S,4R,5R,6R)-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-yl]indol-1-yl]methyl]phenyl]but-3-enoic acid
• CAS: 887338-15-0
• 化学式: C₅₄H₅₃NO₇
• 分子量: 828.017
• InChiKey: ZLHNTTUPGTUZME-NXLBSOBJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.2
• 重原子数：
  62
• 可旋转键数：
  19
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  88.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-1-[4-((1E)-3-carboxyprop-1-enyl)benzyl]-7-methyl-1H-indole 、 2-苄氧基乙醇 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 3-(2,3, 4, 6-tetra-O-benzyl-β-D-glucopyranosyl)-1-(4-((1E)-3-[2-(benzyloxy)ethoxycarbonyl]prop-1-enyl}benzyl)-7-methyl-1H-indole
  参考文献：
  名称：

  1-SUBSTITUTED-3- BETA-D-GLYCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME

  摘要：

  公开号：

  EP1813611B1

文献信息

• 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME
  申请人：Yonekubo Shigeru

  公开号：US20090074738A1

  公开（公告）日：2009-03-19

  A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, —O—, —S— or —NH—; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom.

  一种具有SGLT1和/或SGLT2抑制活性的化合物，可用作预防或治疗糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症、肥胖等的药物。该化合物是一种1-取代-3-(β-D-葡萄糖苷基)氮杂环化合物，其通式表示为(I)，其前药，或其药学上可接受的盐，或其水合物或溶剂化物；包含该化合物的SGLT抑制剂；包含该化合物的制药组合物和药物组合制剂。在该式中，A代表烷基或烯烃基；B代表单键，—O—，—S—或—NH—；C代表可选择取代的芳基或杂芳基；Q独立地表示氢原子或取代基结合的碳原子或氮原子。
• 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US07750145B2

  公开（公告）日：2010-07-06

  A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, —O—, —S— or —NH—; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom.

  具有SGLT1和/或SGLT2抑制活性的化合物，可用作预防或治疗糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症、肥胖等药物。它是一种1-取代-3-（β-D-葡萄糖苷基）含氮杂环化合物，代表通式（I），其前药，或其药学上可接受的盐，或其水合物或溶剂化物；含有SGLT抑制剂的化合物；含有该化合物的制药组合物。在该式中，A代表烷基或烯基；B代表单键，-O-，-S-或-NH-；C代表可选取代的芳基或杂环芳基；Q独立地表示氢原子或取代基连接的碳原子或氮原子。
• 1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1813611A1

  公开（公告）日：2007-08-01

  A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, -O-, -S- or -NH-; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom.

  一种具有 SGLT1 和/或 SGLT2 抑制活性的化合物，可用作预防或治疗糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症、肥胖症等的药物。它是由通式（I）代表的1-取代-3-（β-D-吡喃糖基）含氮杂环化合物、其原药或其药学上可接受的盐，或其水合物或溶液；含有相同物质的SGLT抑制剂；含有相同物质的药物组合物以及它们的组合药剂。式中，A代表烯基或烯基；B代表单键、-O-、-S-或-NH-；C代表任选取代的芳基或杂芳基；Q独立地代表氢原子或取代基结合的碳原子或氮原子。
• US7750145B2
  申请人：——

  公开号：US7750145B2

  公开（公告）日：2010-07-06